PMID- 36074320
OWN - NLM
STAT- MEDLINE
DCOM- 20230106
LR  - 20230111
IS  - 1880-4233 (Electronic)
IS  - 1340-6868 (Print)
IS  - 1340-6868 (Linking)
VI  - 30
IP  - 1
DP  - 2023 Jan
TI  - Patient preferences for features of HER2-targeted treatment of advanced or 
      metastatic breast cancer: a discrete-choice experiment study.
PG  - 23-35
LID - 10.1007/s12282-022-01394-6 [doi]
AB  - BACKGROUND: We aimed to quantify patients' benefit-risk preferences for 
      attributes associated with human epidermal growth factor receptor 2 
      (HER2)-targeted breast cancer treatments and estimate minimum acceptable benefits 
      (MABs), denominated in additional months of progression-free survival (PFS), for 
      given treatment-related adverse events (AEs). METHODS: We conducted an online 
      discrete-choice experiment (DCE) among patients with self-reported 
      advanced/metastatic breast cancer in the United States, United Kingdom, and Japan 
      (N = 302). In a series of nine DCE questions, respondents chose between two 
      hypothetical treatment profiles created by an experimental design. Profiles were 
      defined by six attributes with varying levels: PFS, nausea/vomiting, diarrhea, 
      liver function problems, risk of heart failure, and risk of serious lung damage 
      and infections. Data were analyzed using an error component random-parameters 
      logit model. RESULTS: Among the attributes, patients placed the most importance 
      on a change in PFS from 5 to 26 months; change from no diarrhea to severe 
      diarrhea was the least important. Avoiding a 15% risk of heart failure had the 
      largest MAB (5.8 additional months of PFS), followed by avoiding a 15% risk of 
      serious lung damage and infections (4.6 months), possible severe liver function 
      problems (4.2 months), severe nausea/vomiting (3.7 months), and severe diarrhea 
      (2.3 months) compared with having none of the AEs. The relative importance of 21 
      additional months of PFS (increasing from 5 to 26 months) increased for women 
      with HER2-negative disease and those with children. CONCLUSIONS: Patients valued 
      PFS gain higher than the potential risk of AEs when deciding between hypothetical 
      breast cancer treatments.
CI  - (c) 2022. The Author(s).
FAU - Mansfield, Carol
AU  - Mansfield C
AUID- ORCID: 0000-0002-3144-8938
AD  - RTI Health Solutions, Research Triangle Park, NC, USA. carolm@rti.org.
FAU - Botha, Willings
AU  - Botha W
AD  - RTI Health Solutions, Manchester, UK.
FAU - Vondeling, Gerard T
AU  - Vondeling GT
AD  - Daiichi Sankyo Europe, Munich, Germany.
FAU - Klein, Kathleen
AU  - Klein K
AD  - RTI Health Solutions, Research Triangle Park, NC, USA.
FAU - Wang, Kongming
AU  - Wang K
AD  - Daiichi Sankyo Inc, Basking Ridge, NJ, USA.
FAU - Singh, Jasmeet
AU  - Singh J
AD  - Daiichi Sankyo Inc, Basking Ridge, NJ, USA.
FAU - Hackshaw, Michelle D
AU  - Hackshaw MD
AD  - Daiichi Sankyo Inc, Basking Ridge, NJ, USA.
LA  - eng
PT  - Journal Article
DEP - 20220908
PL  - Japan
TA  - Breast Cancer
JT  - Breast cancer (Tokyo, Japan)
JID - 100888201
SB  - IM
MH  - Child
MH  - Humans
MH  - Female
MH  - United States
MH  - *Breast Neoplasms/drug therapy
MH  - Patient Preference
MH  - Progression-Free Survival
MH  - Nausea
MH  - Vomiting
PMC - PMC9454390
OTO - NOTNLM
OT  - Conjoint analysis
OT  - Discrete choice
OT  - Risk-benefit
OT  - Trade-off
COIS- KW and JS are employees of Daiichi Sankyo, Inc. GTV and MDH were employees of 
      Daiichi Sankyo, Inc., when this research was conducted. CM, WB, and KK are 
      employees of RTI Health Solutions, which received funding from Daiichi Sankyo, 
      Inc. to conduct the study.
EDAT- 2022/09/09 06:00
MHDA- 2023/01/07 06:00
PMCR- 2022/09/08
CRDT- 2022/09/08 11:21
PHST- 2022/02/01 00:00 [received]
PHST- 2022/08/08 00:00 [accepted]
PHST- 2022/09/09 06:00 [pubmed]
PHST- 2023/01/07 06:00 [medline]
PHST- 2022/09/08 11:21 [entrez]
PHST- 2022/09/08 00:00 [pmc-release]
AID - 10.1007/s12282-022-01394-6 [pii]
AID - 1394 [pii]
AID - 10.1007/s12282-022-01394-6 [doi]
PST - ppublish
SO  - Breast Cancer. 2023 Jan;30(1):23-35. doi: 10.1007/s12282-022-01394-6. Epub 2022 
      Sep 8.